Daniel A. Morgenstern

机构：University of Toronto, Hospital for Sick Children, SickKids Foundation · ORCID：0000-0002-4859-1108

发表论文 264 篇 · 总被引 4309 次 · h-index 33

代表论文

• The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial (2025 · Nature Communications · 被引 33)
• Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024 · JAMA Oncology · 被引 27)
• Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors (2025 · Journal of Clinical Oncology · 被引 14)
• Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum (2025 · Pediatric Blood & Cancer · 被引 13)
• DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition (2025 · Cell Reports · 被引 7)
• Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia (2025 · Pediatric Blood & Cancer · 被引 6)